Haleon plc research snapshot
HLN AI stock analysis currently views Haleon as a global consumer-health company with trusted brands, recurring everyday demand, improving productivity, and solid free cash flow. The counterweight is modest reported growth, currency exposure, leverage, and the need to turn oral-health momentum into broader category growth. The AI view is a watchlist-to-selective-accumulation framework, not a precise price prediction or personal investment recommendation.
Current price
$9.77
Market cap
$42.54 billion
AI score
68 / 100
Rating
Defensive consumer-health quality with execution and valuation discipline required
Trend status
Recovering from a June low, with price testing the $9.70 to $9.80 resistance area
Data cutoff (updated weekly)
July 11, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Haleon sells everyday self-care products across Oral Health, VMS, Pain Relief, Respiratory, Digestive, and Therapeutic Skin Health categories. | High |
| Moat | Brands such as Sensodyne, parodontax, Advil, Centrum, Panadol, Voltaren, and Theraflu support shelf access and consumer trust, though private labels and category competition limit pricing power. | Medium-high |
| Management | CEO Brian McNamara and CFO Dawn Allen are pursuing productivity, growth investment, buybacks, and a leverage target around 2.5x net debt to adjusted EBITDA. | Medium |
| Financial trend | FY2025 reported revenue was £11.03bn, down 1.8%, while organic revenue grew 3.0%, adjusted operating profit rose 1.0%, and free cash flow was £1.913bn. | High |
| Valuation | Using a July 2026 London price reference of 363.5p and FY2025 diluted EPS of 18.5p, the audited calculation is about 19.6x earnings and 17.1x free cash flow. | Medium |
| Technical trend | The ADR rebounded from the June $8.77 low to about $9.77, but it is approaching short-term resistance near $9.80 to $10.00 rather than confirming a completed breakout. | Medium-low |
| Risk level | Key risks are consumer and retailer weakness, seasonal respiratory demand, foreign exchange, debt refinancing, input costs, regulation, and execution of the new operating model. | High |
| AI confidence | Reported financial and company data are well documented; forward returns remain conditional on execution and valuation changes. | High data confidence |
| Investment certainty | The business is understandable and cash generative, but the entry decision still needs a margin of safety and confirmation that volume and categories broaden beyond Oral Health. | Medium |
HLN AI stock forecast
The HLN AI stock forecast is a scenario framework rather than a promised target. A three-year calculation using FY2025 adjusted EPS of 18.8p, a July 2026 reference price of 363.5p, and distinct growth and multiple assumptions produces a wide range of outcomes.
About 520p, or roughly $14 per ADR at a similar FX rate
More likely if organic growth returns to the 4% to 6% medium-term range, Oral Health and innovation broaden across regions, supply-chain savings expand margins, debt falls, and the market assigns a 22x earnings multiple.
About 390p, or roughly $10 to $11 per ADR at a similar FX rate
More likely if adjusted EPS compounds about 5%, FY2026 guidance is met, free cash flow supports dividends and buybacks, and the market holds an 18x earnings multiple.
About 270p, or roughly $7 to $8 per ADR at a similar FX rate
More likely if weak consumer demand or respiratory seasons persist, volumes erode, leverage remains elevated, currency turns adverse, or the valuation compresses toward 14x earnings.
HLN AI technical analysis
HLN AI technical analysis uses the latest independently available ADR price history through July 10, 2026. The stock closed at $9.73 on July 9 and traded at $9.77 intraday on July 10. These levels are a price-action framework, not a live chart feed, and should be refreshed before any trading decision.
| Level | Value | Why it matters |
|---|---|---|
| Current price reference | $9.73 close on July 9; $9.77 intraday on July 10 | StockAnalysis daily history and statistics page, last checked July 11, 2026. |
| Immediate support | $9.55 to $9.60 | Recent July trading clustered around this area before the move toward $9.70. |
| Lower support | $9.20 to $9.30 | This zone held repeatedly in late May and June. A sustained break would weaken the recovery thesis. |
| Near resistance | $9.80 to $10.00 | The July 9 high was $9.74; a decisive close through this round-number area would be a clearer short-term confirmation. |
| 50-day moving average | Approx. $9.30 to $9.50 | Estimated from available May through July daily closes, not a direct live technical-indicator feed. |
| 200-day moving average | Not independently verified for this cutoff | Use a current chart before relying on this long-term trend signal. |
| Momentum | Improving from the June low, not yet independently confirmed by RSI | The stock rose from $8.77 on June 22 to $9.73 on July 9, but this page does not claim a live RSI value. |
| Volume | 6.4M shares on July 9 | Compare future breakout volume with the recent daily range of roughly 6M to 13M shares. |
| Volatility marker | $8.77 to $9.84 in late June and early July | Recent price history shows a narrow but meaningful range for risk sizing. |
| Invalidation | Sustained close below $9.20 | A break of the repeated late-May and June support zone would invalidate the near-term recovery setup. |
HLN AI trading strategy
The HLN AI trading strategy is a rules-based research framework, not personal advice. It pairs category and cash-flow evidence with an observable price level and a predefined invalidation condition.
Watch for a close above $9.80 to $10.00 followed by support holding on a retest. Confirm with higher volume and evidence that FY2026 organic growth is tracking the 3% to 5% company guide.
Treat a close back below the breakout zone or a sustained break below $9.20 as a rules-based invalidation signal.
If HLN revisits $9.20 to $9.30, compare the price action with Q2 results, respiratory demand, volume trends, free cash flow, and net-debt progress before assuming support will hold.
Do not average down solely because the company has defensive brands. Size risk for a support failure and changing consumer or retailer conditions.
Track organic revenue by region and category, Oral Health growth, volume versus price, adjusted operating margin, free cash flow, net debt to adjusted EBITDA, buybacks, dividend coverage, and currency effects.
Reassess the thesis if low volume/mix persists, guidance is reduced, leverage moves away from the medium-term target, or savings do not translate into cash returns.
Investment research summary
Haleon sells self-care and over-the-counter health products. Consumers and health professionals pay for recognizable brands, product efficacy, availability, and habitual use in everyday health categories.
Its moat rests on trusted brands, global distribution, retailer shelf space, scientific and regulatory capabilities, and marketing scale. It is not absolute: private labels, rival brands, retailer concentration, and slower category demand can narrow it.
The thesis can fail if consumers trade down, cold and flu seasons stay weak, price increases outpace volume, innovation does not scale, foreign exchange absorbs operating gains, or leverage limits capital allocation flexibility.
Brian McNamara leads Haleon, with Dawn Allen as CFO. The key management tests are delivery of operating-model savings, disciplined brand investment, successful buybacks at sensible valuations, and steady progress toward the roughly 2.5x net-debt-to-adjusted-EBITDA target.
Consumer health benefits from ageing populations, health awareness, self-care, and emerging-market access. It also faces regulation, reimbursement or channel changes, generics and private labels, local competition, and uneven consumer confidence.
At the 363.5p July reference price, the audited calculation is about 19.6x FY2025 diluted earnings and 17.1x free cash flow. A margin of safety depends on growth and productivity actually improving while debt declines, not on assuming defensive brands will always deserve a premium multiple.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| HLN ADR price | $9.73 close on July 9, 2026; $9.77 intraday on July 10 | StockAnalysis price history and statistics | July 11, 2026 |
| Market cap | $42.54 billion | StockAnalysis statistics | July 11, 2026 |
| Share count and market-cap check | 8.982 billion FY2025 basic weighted-average ordinary shares; 363.5p x 8.982bn = about £32.65bn | Haleon 2025 Annual Report and Pineify financial_rigor.py calculation | July 11, 2026 |
| FY2025 revenue | £11.030 billion, reported decline 1.8%, organic growth 3.0% | Haleon 2025 Annual Report and StockAnalysis | July 11, 2026 |
| FY2025 profit attributable to shareholders | £1.667 billion; diluted EPS 18.5p | Haleon 2025 Annual Report and StockAnalysis | July 11, 2026 |
| FY2025 adjusted operating profit and margin | £2.526 billion and 22.9% | Haleon 2025 Annual Report | July 11, 2026 |
| FY2025 free cash flow | £1.913 billion | Haleon 2025 Annual Report and FY2025 results statement | July 11, 2026 |
| Net debt | £7.263 billion at Dec. 31, 2025, or 2.6x adjusted EBITDA | Haleon 2025 Annual Report | July 11, 2026 |
| Q1 2026 trading update | Revenue £2.857 billion and organic growth 2.2%; FY2026 guide reiterated at 3% to 5% organic revenue growth and high-single-digit adjusted operating-profit growth at constant currency | Haleon Q1 2026 Trading Statement | July 11, 2026 |
| FY2026 consensus context | Published company-hosted consensus: £11.394 billion revenue, 20.6p adjusted EPS, and 7.4% organic operating-profit growth | Haleon consensus page, analyst estimates not company guidance | July 11, 2026 |
This HLN AI stock analysis is an informational research tool only and is not investment advice, a recommendation, or a guarantee of future returns. Forecast scenarios use available public data as of July 11, 2026 and can be wrong if earnings, consumer demand, currency, valuation multiples, or market conditions change.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
